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Abstract
Background Chronic viral infections caused by highly contagious human papillomaviruses (HPVs) from the alpha
genus are a substantial risk factor for tumour diseases.
Objectives The goal of this study was to compare the HPV infection pattern with histology in a patient group of
immunocompromised HIV+ and non-immunocompromised patients with anal intraepithelial neoplasia.
Materials and Methods Tissue samples (n = 210) from the anogenital area of 121 patients underwent retrospective his-
tological and molecular examination for HPV DNA prevalence by chip analysis. The study was part of a cancer screening
from the Dermatology Department of the LMUMunich, Germany. All data were collected and processed anonymously.
Results HPV 6 or 11 are more abundant in tissue samples from histologically diagnosed condylomata acuminata
(47.7%) compared to grade 1, 2, and 3 intraepithelial neoplasias (IN 1-3). Detection of high-risk (hr) alpha-HPV DNA was
signiﬁcantly higher in tissue samples from IN 3 (67.5%) compared to IN 1 and 2 (12.9%), and compared to condylomata
acuminata (29.5%). No HPV types were detected in histologically unremarkable tissue samples. There was a signiﬁcant
association between the prevalence of HPV 16 and the classiﬁcations IN 1 to IN 3 (v2 (2) = 13.62, P = 0.001). We identi-
ﬁed a signiﬁcant correlation between the prevalence of high-risk and low-risk (lr) HPV types and HIV, especially mixed
infections of different HPV types correlated with high-grade IN. Based on the present data, we suggest the risk of carci-
noma in HIV+/ patients (RICH) score and test it in the 121 patients.
Conclusions hr alpha-HPVs, mainly HPV 16, are associated with increased oncogenic potential of premalignant
lesions (IN 1-3), especially in HIV+ patients. Based on the combination of HIV/HPV-testing and histological analysis, we
identiﬁed correlations that could potentially forecast the risk of malignant transformation and summarized them in the
form of RICH score.
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Introduction
Chronic viral infections are a major risk factor for neoplastic dis-
eases and of high interest in clinical research.1 Of the 2.2 million
new cancer cases attributable to carcinogenic infections world-
wide in 2012, 640 000 were caused by human papillomaviruses,
thus constituting the second largest contributor to the carcino-
genic infections after Helicobacter pylori (770 000 cases).2 Human
papillomaviruses belong to the ever-growing family of
papillomaviridae, as defined by the International Committee for
Taxonomy of Viruses (ICTV). They are non-enveloped DNA
viruses with a small, annular, double-stranded genome consisting
of about 6.800-8.000 bp.3 Based on their DNA, five genera can be
subdivided in more than 225 genotypes of papillomaviridae: alpha
(a)-papillomavirus, beta (b)-papillomavirus, gamma (c)-papillo-
mavirus, mu (l)-papillomavirus and nu (m)-papillomavirus.4
Human papillomaviruses infect multi-layered epithelia like ker-
atinocytes of the mucosa or cutaneous epithelium, and can also be
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subdivided into so-called ‘low-risk’ (lr) and ‘high-risk’ (hr) HPVs,
based on their risk of inducing neoplastic transformation.5,6
Alpha-papillomaviruses mainly infect the anogenital tract and
can cause various benign and malignant tumours according to
their oncogenic potential.7 The main risk factor for the develop-
ment of anogenital squamous cell carcinoma (SCC) is the persis-
tent infection with hr HPV.8 In cervical carcinoma, hr HPV
types were detected in 99.7 % of cervical cancers.9 Furthermore,
hr HPVs are associated with 43 % of vulvar cancers, with 50 %
of penile carcinomas, with 70 % of vaginal carcinomas and with
88 % of anal carcinomas of both sexes.10 The dominant hr HPV
types in anogenital carcinomas are HPV 16 (range, 40.9–
82.2 %) and HPV 18 (44.7 % of adenocarcinomas of the cervix,
2.6–18.1 % at other locations).11
The human pathogenic papillomaviruses are strictly epithe-
liotropic. Most HPV infections are transient infections, asymp-
tomatic or subclinical and therefore not recognized. They
usually heal in about 4 to 20 months and do not cause neo-
plasia,12 whereas in some cases, for example in HIV+ patients,
HPV infections can increase the incidence of cancer.13–15 The
overall life expectancy of HIV+ patients has increased in the last
two decades due to the wide use of antiretroviral therapy
(ART).16–18 Additionally, anal intraepithelial neoplasia of grade
2 or 3 can be reduced by using quadrivalent HPV vaccines in
men who have sex with men (MSM).19
Nowadays, the incidence of cervical cancer can be reduced by
83 % through specific precautionary vaccination against the
HPV types 16,18, 31, 33, and 45.20
The aim of this study was to compare the HPV infection pat-
tern with histology in immunocompromised and non-immuno-
compromised patients. Moreover, the histological grading was
compared to the molecular analysis to distinguish the different
entities. Based on the results, a predictive score was established
and evaluated to determine the risk of developing IN in
immunocompromised patients. This score is expected to
improve clinical assessment.
Materials and methods
Patient population
The patient collective of this retrospective study consists of
patients presenting at the Department of Dermatology of the
Ludwig-Maximilian-University in Munich, Germany, from
February 2010 to August 2015 who were treated according to
the guidelines for prevention of anal cancer of the German
AIDS Society. The study was independent of gender, age or
nationality. All data were collected and processed anony-
mously.
Ethics committee
The ethics committee of LMU Munich reviewed and approved
the ethical safety of the planned fully anonymized retrospective
study of the prevalence of HPV types in diagnostic scans and tis-
sue samples of cutaneous neoplasia in immunosuppressed and
non-immunosuppressed patients.
Data collection
The data were collected from the electronic patient file. Addi-
tionally, for diagnostic purposes stored biopsies were re-analysed
for HPV types.
Statistical evaluation
All data were statistically analysed with SPSS (Statistics Version
23 IBM Inc, Armonk, NY, USA). The corresponding images
were generated using GraphPad Prism 5 software (GraphPad
Software Inc., La Jolla, CA/USA). Significance testing (signifi-
cance level a = 0.05) was performed using the Pearson chi-
square test and Fisher’s exact test. The strength of each effect
was determined by Cramer’s V test.
Patient group
Out of 150 patients, 29 patients (19.3 %) had to be excluded
from this study because of incomplete data sets or insufficient
tissue material. The gender distribution of the remaining 121
patients included 14 women (11.6 %) and 107 men (88.4 %).
The mean patient age (years  SD) was 47.8  14.3 years.
The youngest patient was 24 years, the oldest 87 years old.
Tissue samples
Anogenital biopsy tissue samples were taken during clinical rou-
tine controls that included biopsy and were stored in the histo-
logical archive. For this study, they were retrospectively analysed
and tested for HPV.
Samples were collected from February 2010 to August 2015,
fixed with 10 % formalin (Merck KGaA, Darmstadt, Germany),
paraffin (Merck KGaA) embedded and HE-stained (Merck
KGaA, Darmstadt, Germany). Originally, only HIV+ patients
were considered. However, we did not find enough HIV+
patients to test for HPV types. Therefore, we analysed samples
from our histological database (ZOC-Database).
One or more tissue samples from each patient were analysed
retrospectively. In total, 245 tissue samples were analysed; after
the presence of tissue in the paraffin-embedded samples could
be confirmed, a total of 210 (85.7 %) tissue samples underwent
further histological and molecular genetic analysis.
From 59 patients (48.8 %) one tissue sample, from 39 patients
(32.2 %) two tissue samples, from 20 patients (16.5 %) three tis-
sue samples, from two patients (1.7 %) four tissue samples and
from one patient (0.8 %) five tissue samples were collected.
Histological evaluation
All 210 tissue samples underwent histopathological examination
by a board-certified dermatohistopathologist who assigned them
to their diagnostic entities.
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Localization distribution
Tissue samples were evaluated according to their localization
and gender distribution. In male patients, 13 perianal (7.0 %),
20 anal (10.8 %), 32 penile (17.2 %) and 121 intraanal (65.0 %)
tissue samples were collected. In female patients, one anal
(4.2 %), one perianal (4.2 %), 8 intraanal (33.3 %) and 14 vul-
val (58.3 %) tissue samples were collected.
HIV status distribution depending on gender
The examined samples were divided in terms of gender and the
presence of HIV disease. Of the 107 male patients, 59 (55.1 %)
were HIV-positive, 22 (20.6 %) were HIV-negative, and in 26
(24.3 %) patients, the HIV status was unknown. Out of 14 female
patients, three (21.4 %) were HIV-positive, seven (50.0 %) were
HIV-negative, and four (28.6 %) had an unknown HIV status.
Chip analysis: Low-cost density (LCD) array HPV Type 3.5
The DNA chips from Chipron (Berlin/Germany) were developed
for the identification and differentiation of clinically relevant
human alpha-papillomaviruses, in total 32 different types (6, 11,
16, 18, 31, 33, 35, 39, 42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62,
66, 67, 68, 70, 72, 73, 81, 82, 83, 84, 90, 91). The kits consist of a
primer system as well as HPV-chip arrays. The primer system
‘MY09/11’ is based on the sequences MY09 and MY11 and gen-
erates PCR amplifications of the size of about 450 base pairs. To
prove the overall conditions (primer quality, PCR success), an
agarose gel electrophoresis preceded the chip analysis. Besides,
the additional PCR kit was performed according to the manufac-
turer’s instructions and evaluated with the company’s SlideRea-
der and V12 software (Chipron).
Generation of the RICH (Risk of Carcinoma in HIV+
patients) score
Based on the histological findings, chip analysis and serological
HIV testing, the RICH score was generated and patients tested
accordingly.
Results
Histological grading
Out of 114 (54.3 %) tissue samples with an IN, 15 samples dis-
played a grade 1 (IN 1), 16 samples a grade 2 (IN 2) and 83 sam-
ples a grade 3 (IN 3) neoplasia. Those tissue samples were
obtained from the anal, the vulvar or the penile area. 88 of the
210 specimens (41.9 %) were histologically diagnosed as condy-
lomata acuminata. Eight (3.8 %) samples were histologically
inconspicuous.
Distribution of hr HPV, lr HPV and mixed infections in
comparison with histological ﬁndings
Tissue samples were subdivided into four HPV status dependent
groups: Without HPV, high-risk HPV (hr HPV) only, low-risk
HPV (lr HPV) only and mixed infections (hr HPV and lr HPV).
These groups were compared with respect to their histological
findings ranging from unremarkable, IN 1, IN 2, IN 3, and
condylomata acuminata. Of the 32 potentially detectable HPV
types, DNA from HPV 35, 51, and 73 was never detected. All
other types delivered type-specific results with incidences
between approximately 1 % and 50 % (data not shown). No evi-
dence for present HPV DNA could be found in any of the speci-
mens that were histologically unremarkable. In the IN 1 group,
the hr HPV type 16 was identified in one sample (6.7 %), while
the remaining 14 samples were HPV negative or contained at
least one lr HPV type. In the IN 2 group, at least one hr HPV
type was identified in three samples (18.9 %). 13 samples were
HPV negative or contained at least one lr HPV type. In the IN 3
group, at least one hr HPV type was identified in 56 samples,
while 27 samples were HPV negative or contained at least one lr
HPV type. This corresponds to a prevalence of hr HPV in 67.5 %
of the IN 3 samples. Within the group of condylomata acumi-
nata, four samples out of 88 in total were positive for at least one
hr HPV type and 22 samples for at least one hr HPV type in com-
bination with one or more lr HPV types. Hr HPV prevalence was
29.5 % among all condylomata acuminata. (Table 1)
Comparison of HPV detection using chip versus
histological analysis
The detection of the HPV types in IN 3 showed the same sensi-
tivity when the molecular analysis and the histological method
were compared. For the HPV types IN 1 and IN 2, the molecular
analysis was less sensitive compared with histology (Fig. 1).
Analysis of histological grading and molecular genetic HPV
detection
Hr HPV and lr HPV were compared to their histological grad-
ing. There was a significant correlation between the presence of
hr or lr HPV types and the histology (v2 (3) = 44.51, P ≤ 0.001
/ Fisher’s exact test: P ≤ 0.001) (Table 2).
Correlation analysis of condylomata acuminata and lr HPV type
6 and 11: Between condylomata acuminata, unremarkable, and
IN 1 and 2, no significant difference in the prevalence of general
lr HPV types could be determined. The effect is of medium
strength with Cramer’s V = 0.46.
70 out of 88 condylomata acuminata (79.5 %) samples
were positive for lr HPV 6 or 11 with HPV 6 infection being
the most prevalent type of single HPV infection (34.1 % of
all condylomata samples), followed by single HPV 11 infec-
tion (13.6 %).
These two types were observed at an above-average frequency
of 47.7 % in condylomata acuminata in comparison to IN 1, IN
2 and IN 3 (v2 (3) = 40.97, P ≤ 0.001). This effect is of medium
strength (Cramer’s V = 0.44). Co-infection of HPV 6 and HPV
11 could not be detected in any of the analysed samples.
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Correlation analysis of the histological grading and the molecu-
lar genetic analysis of hr HPV types: Overall, we observed a
significant difference in hr HPV prevalence of the IN 3 group
(67.5 %) compared with IN 1, IN 2 (12.9 %) and condylomata
acuminata (29.5 %). Detection of any hr HPV type was observed
in 65.1 % of examined IN 3 samples. HPV 16 was the most
dominant type and was detected in 50.6 % of all IN 3 samples.
There was a significant correlation between the prevalence of
HPV 16 (but without HPV 18) and the classifications IN 1 to IN
3 (v2 (2) = 13.62, P ≤ 0.001). This effect is of medium strength
(V = 0.35). Moreover, in IN 3 samples 80.4 % of the total hr
HPV infections were single hrHPV infections with HPV 16 being
the most prevalent single infection (34.9 %). Only 18.2 % of hr
HPV infections were single infections in the lesions histologically
identified as condylomata acuminata. There was no significant
correlation between the prevalence of HPV 18 (without HPV
16) and oncological grading (exact Fisher test: P = 0.725,
V = 0.09).
Comparison of HIV status, molecular genetic results and
histological ﬁndings
A significant correlation was observed between the prevalence of
hr and lr HPV types and the oncological grading based on histol-
ogy in all three groups (HIV+, HIV, HIV unknown; p ≤ 0.01).
Accordingly, hr HPVs predominated the IN 3 samples of all
three groups unaffected by the HIV status. However, a higher
percentage of hr HPV types was detected in the IN 3 samples of
patients of HIV/unknown status (82.4 % and 72.7 %, respec-
tively) compared with those of HIV+- patients (59.1 %). In
contrast, in the condylomata acuminata and in the IN 1 and 2 of
HIV+-patients a higher percentage of hr HPV types was identi-
fied than in patients with HIV/unknown status. On the other
hand, HIV+ patients showed the highest percentage (40.9 %) of
lr HPV types throughout the IN 3 samples compared with
patients of HIV/unknown status (17.6 % and 27.3 %), while
overall in the condylomata acuminata and in IN 1 and 2 samples
of all patients the highest amount of lr HPVs could be detected.
(Table 3)
Introduction of the RICH score
Based on our results, we introduce the RICH score that is calcu-
lated using the data received from histology, chip analysis and
serological HIV testing combined (Table S1). Based on the histo-
logical finding, we suggest attributing 3 points to an IN 3 confir-
mation, two points to an IN 2 diagnosis and 1 point if IN 1 or
condylomata acuminata are detected. A chip analysis detecting
hr HPVs adds 2 points to the score, lr HPVs add 1 point, while
the detection of both lr and hr HPVs adds 3 points. Moreover,
HIV+ patients receive additional 3 points, whereas HIV- patients
are not additionally scored. Scores <3 are a reference point to
proceed with normal screening procedures once a year. Patients
with scores between 3 and 4 should pay particular attention and
consult a doctor semi-annually or whenever they recognize signs
of disease progression. Scores >4 recommend precise screening
every 3 months, including high-resolution anal anoscopy and
biopsy (Fig. 2). Given the case that only cytology/HPV status
and HIV status are available, we suggest screening procedures
every 3 months if patients receive a score >2.
Testing the efﬁcacy of the RICH score in 121 patients
The data of the 91 fully assigned (with available HIV status)
patients were used to assess their RICH score (Fig. 3). Of note,
most patients were HIV+ and therefore commonly had RICH
scores >4, receiving recommendation for precise screening pro-
cedures every three months. Moreover, the RICH score could
clearly separate patients that have a low risk of disease progres-
sion.
Discussion
Human alpha-papillomavirus infections are increasingly related
to malignancy of tumours in female and male individuals.7,21
Histology
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Figure 1 Frequency distribution of HPV types in entities IN 1-3
and their correlation and comparison of histology and molecular
analysis in the distribution of the HPV types.
Table 2 HPV detection via histological grading and molecular analysis
Unremarkable Condyl. ac. IN 1 + 2 IN 3 Total
N % N % N % N % N %
lr HPV All lr HPV types 8 0 62a 70.5 27a 87.1 27b 32.5 124 59
HPV 6 + 11 only 0a,b 0 42a 47,7 3b 9,7 8b 9,6 53 25,2
hr HPV All hr HPV types 0 0 26a 29.5 4a 12.9 56b 67.5 86 41
The superscript letters should be read line by line.
Different superscript letters indicate a signiﬁcant difference (P ≤ 0.05, correction of Bonferroni’s signiﬁcance level).
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While condylomata acuminata belong to HPV-induced benign
tumours, long-lasting infection with oncogenic HPV types can
cause IN in anogenital areas as well as anogenital carcinoma.22–24
HPV types 16 and 18 are already prevalent in 60-70 % of
premalignant cases.8
HIV/HPV co-infection
Immunocompromising diseases like HIV infections encourage
HPV infection and strongly increase the risk of developing IN or
anogenital carcinoma.22,25 In accordance with this correlation,
hr HPV types were detected in only 15.4 % of the condylomata
acuminata of HIV patients. In contrast, hr HPV types were pre-
sent in 47.5 % of HIV+ patients with condylomata acuminata.
This indicates that HIV may also increase the risk of malignant
transformation of condylomata acuminata.26 Surprisingly, this
correlation could not be confirmed in the entity of IN 3 which
showed a decrease of hr HPV types in HIV+ samples, but an
increase in lr HPV types. However, information about the dura-
tion of HIV infection as well as the HIV status in 23.8 % of the
samples is missing. Another limitation is the heterogeneous
group of samples (perianal, anal, penile, vulvar) and small sam-
ple numbers in some of the subgroups. Moreover, this study
lacks a T-cell count correlating with immune function. For-
merly, therapy derived immunosuppression was supposed to
have no influence on the infection with HPV.22 Literature about
HPV status under immunosuppression is controversial, and our
data clearly indicate a correlation between HIV prevalence and
HPV infection.
Chip testing vs. histology
In IN 1 and 2, the molecular analysis was more sensitive in
detecting HPV types compared to histological examination. The
detection sensitivity in IN 3 was however similar using both
Table 3 Distribution of hr HPV and lr HPV according to HIV status and compared to histological grading
P<0.001 Unremarkable Condyl. ac. IN 1+2 IN 3 Total
N % N % N % N % N %
HIV  Low-risk 2a,b 100 22 84.6 2a,b 100 3b 17.6 29 61.7
High-risk 0a,b 0 4 15.4 0a,b 0 14b 82.4 18 38.3
HIV + Low-risk 6a 100 21a,b 52.5 19a 82.6 18b 40.9 64 56.6
High-risk 0a 0 19a,b 47.5 4a 17.4 26b 59.1 49 43.4
HIV? Low-risk – – 19a 86.4 6a 100 6b 27.3 31 62
High-risk – – 3a 13.6 0a 0 16b 72.7 19 38
The superscript letters should be read line by line.
Different superscript letters indicate a signiﬁcant difference (P ≤ 0.05, correction of Bonferroni’s signiﬁcance level).
Question mark indicates unknown HIV status.
Figure 2 Dendrogramm for the evaluation of the RICH score. This
screening score is calculated by going through the dendrogram
from the top to the bottom, thereby building the sum of the
numbers. The score can still be used if histology is not available
(without the light grey part).
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Figure 3 Distribution of patients among RICH scores from 1 to 9.
Green bars for low-risk, orange bars for intermediate-risk, red bars
for high-risk patients.
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methods. We hereby conclude that molecular analysis is more
precise in distinguishing HPV types in IN 1 and 2. This might be
due to the sensitivity of this PCR based method, being able to
detect low amounts of HPV DNA.
Correlation of hr HPV with the oncologic grade (IN 1-3)
We observed an increased hr HPV prevalence that correlates
positively with a higher oncological grade: IN 1 (hr
HPV = 41.9 %) compared to IN 3 (hr HPV = 86.7 %).
Among both entities an increase of hr HPV 16 (IN
1 = 6.67 %, IN 3 = 50.6 %) and HPV 18 (IN 1 = 0 %, IN
3 = 7.2 %) was detected.
In 13.3 % of IN 3 samples, no HPV was detected. We specu-
late that not enough DNA material was present. Another reason
might be that the used chip detected only 32 of over 200 yet dis-
covered HPV types. Based on our data, we speculate that the
potentially not detected HPV types may still have oncogenic
potential.
Mixed hr HPV infections as a major risk factor
Most hr HPV mixed infections were observed in IN 3, but not
in condylomata acuminata. We speculate that mixed infections
might increase the risk of malignant transformation. Moreover,
we detected a variety of HPV types and mixed infections even
in low-graded neoplasias (IN 1 and 2). We speculate that low-
graded neoplasias with mixed infections are more likely to turn
into IN 3. That is why even IN 1 and 2 patients with numerous
HPV types should perform regular screening procedures.
Furthermore, it was shown that condylomata acuminata con-
tained many different HPV types. Among these, 29.5 % of the
cases showed hr HPV types (HPV 16 = 13.6 %, HPV 18 =
6.8 %, HPV 39 = 5.7 %). This explains why benign tumours
like condylomata acuminata have oncogenic potential. Hence,
new prevention procedures against HPV infections might be
effectively preventive.
Preventing IN 1-3 by early HPV vaccination
The two vaccines Gardasil (Merck Sharp & Dohme Corp,
USA) and Cervarix (GlaxoSmithKline, UK) revealed high effi-
cacy and cross-protection to other HPV types.20,27 Gardasil 9,
for instance, targets the HPV types 6, 11, 16, 18, 31, 33, 45, 52
and 58.27 After introducing a public vaccination programme in
Australia, a significant decrease of HPV infections was
observed.28,29
Furthermore, HPV vaccination is now recommended for boys
between 9 and 14 (17) years old by the German Standing Com-
mittee on Vaccination (STIKO).30
As IN are the precursor lesions for anogenital carcinomas,23
we find that screening programmes for the recognition and
treatment of HPV infections should be promoted, especially for
immunosuppressive patients.
The American STI-guidelines of the centre for disease control
recommend a vaccination for men to produce herd immunity.31
HPV is mainly sexually transmitted and fulfils the criteria for a
global pandemic. Often young patients in the sexually active age
are affected by HPV infection and therapy is difficult, long-
winded and expensive. The vaccination is approved in many
countries for girls and boys between the ages of 9 and 17 to pre-
vent anogenital dysplasia.32
Introduction of the RICH score
The higher the histopathological grade of anal intraepithelial
neoplasia the higher the risk of developing anal cancer, espe-
cially in HIV+ patients.33 Additionally, almost all precursor
lesions and anal cancers are hr HPV positive, indicating that
early screening procedures are beneficial.23,34 Anal cancer
screening should be performed in all HIV+ patients and high-
risk patients, which are marked by a history of condylomata
acuminata, or IN, or HPV-associated cancer, or persistent hr
HPV infection.35 For example, IN 3 receiving topical treatment
should be repeatedly screened with inspection, palpation, swab,
cytology, anoscopy and if necessary biopsy.35 This is also
reflected in the RICH score which compared to other screening
algorithms (like presented in 35) facilitates the analysis and may
therefore be suitable for clinical routine. We also included
condylomata acuminata in the score since it lacks control and
elimination of an HPV infection (similar to IN 1-3), and it is
also associated with an increased prevalence of anal cancer in
HIV+ patients.35 Condylomata is caused by lr HPV infection,
indicating that even lr HPV types can also be sufficient to
develop anal cancer after persistent infection. To improve the
outcome of yet infected HPV+//HIV+/ patients with anal
intraepithelial neoplasia or condylomata acuminata, we gener-
ated the RICH score. This screening tool was generated based
on our observations and literature and suggests differential
examination intervals based on HIV status, molecular genetic
results and histological findings, similar to studies performed
for anal cancer.36,37 Screening procedures should include high-
resolution anal anoscopy and biopsy. Moreover, patients at low
risk could clearly be separated from high-risk patients, while a
large proportion was assigned to the area between high and low
risk. Especially these patients may be regrouped at their semi-
annual visits. This study though mainly includes HIV+ patients,
which automatically result in high RICH scores. We conclude
that the RICH score offers an easy tool to assign patients to dif-
ferent risk groups.
However, further studies are required to show the outcome of
HIV+ and HIV patients using screening approaches based on
recommendations of the RICH score.
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Supporting information
Additional Supporting Information may be found in the online
version of this article:
Table S1 Calculation of the RICH score from the 121 fully anon-
ymized patients included in this study. Highlighted in yellow are
the results based on histology, HPV and HIV testing that were
used for Figure 3.
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